Nancy U. Lin, MD

In a video interview, Nancy Lin, MD, of Dana-Farber Cancer Institute, talked about an analysis of HERA trial data presented at ESMO Congress.

In a video interview, Nancy Lin, MD, of Dana-Farber Cancer Institute, discussed “interesting updates” from the NATALEE trial presented at ESMO Congress.

Nancy Lin, MD, from the department of medical oncology at Dana-Farber Cancer Institute, discussed exciting OS data from the KEYNOTE-522 study presented at ESMO Congress.

Trastuzumab deruxtecan showed substantial and durable overall and intracranial clinical activity in patients with HER2-positive metastatic breast cancer, according to results from the DESTINYBreast-12 trial presented at ESMO Congress.

Healio spoke with Nancy U. Lin, MD, about metastatic breast cancer, touching on approvals, agents in the pipeline, surveillance, survivorship and other topics impacting clinicians and patients.

Healio spoke with Nancy U. Lin, MD, about metastatic breast cancer, touching on approvals, agents in the pipeline, surveillance, survivorship and other topics impacting clinicians and patients.

Healio spoke with Nancy U. Lin, MD, about metastatic breast cancer, touching on approvals, agents in the pipeline, surveillance, survivorship and other topics impacting clinicians and patients.

Healio spoke with Nancy U. Lin, MD, about metastatic breast cancer, touching on approvals, agents in the pipeline, surveillance, survivorship and other topics impacting clinicians and patients.

Healio spoke with Nancy U. Lin, MD, about metastatic breast cancer, touching on approvals, agents in the pipeline, surveillance, survivorship and other topics impacting clinicians and patients.

Healio spoke with Nancy U. Lin, MD, about metastatic breast cancer, touching on approvals, agents in the pipeline, surveillance, survivorship and other topics impacting clinicians and patients.